Bayosthiti AI, Narayana Health Collaborate to Develop India’s First AI-Based Heart Disease Predictor

The study will analyze transcriptomic data from over 12,000 participants at the Narayana Institute of Cardiac Sciences in Bengaluru.

Bayosthiti AI, an AI-driven healthcare and molecular diagnostics company, has announced a partnership with Narayana Health to develop India’s first artificial intelligence models designed to predict cardiovascular disease in Indian patients.

The study will analyze transcriptomic data from over 12,000 participants at the Narayana Institute of Cardiac Sciences in Bengaluru.

Using Bayosthiti’s proprietary Barcode-Integrated Reverse Transcription (BIRT) technology, researchers will sequence complete RNA profiles from patient blood samples to train AI models capable of detecting molecular patterns that signal coronary artery disease before traditional tests show abnormalities.

Coronary artery disease affects nearly 65 million Indians and often appears earlier than in Western populations. However, existing diagnostic tools remain largely based on European and American datasets, creating what clinicians call a “data gap.” This mismatch leads to missed early indicators in South Asian populations, delaying diagnosis and limiting treatment options.

Narayana Health, which performs over 60,000 cardiac procedures annually, provides the large-scale clinical data necessary to train and validate these AI models. Bayosthiti’s BIRT technology enables cost-efficient sequencing of RNA profiles by processing multiple samples simultaneously, making large-scale genomic studies feasible in India.

Current diagnostic methods rely on imaging or protein markers that detect disease after physical manifestation.

In contrast, RNA sequencing identifies real-time changes in cellular activity, offering the possibility of early detection before damage occurs.

“Just as Google Translate learned language patterns from billions of text examples, our AI learns disease patterns from millions of RNA expressions,” said Dr. Rishabh M. Shetty, head of business development and clinical applications, Bayosthiti AI.

“The transcriptome gives us a real-time readout of what the body is doing right now. Our models can spot the molecular conversation that precedes a heart attack, not just the aftermath, and can do so with the same level of accuracy and efficacy as invasive procedures or other current imaging gold standards,” he added.

Highlighting the significance of the partnership, Dr. PM Uthappa, group chief medical director, Narayana Health, said, “AI-based technologies aren't the future of medicine. They're the present.”

Kutapa Muthanna, CEO, Bayosthiti AI, added, “This isn't just about closing a data gap. It's about building the foundation for proactive, personalized medicine created by Indians, for Indians. When we can tell someone their heart disease risk is rising before any scan shows blockage, we transform care from reactive to preventive.”

Stay tuned for more such updates on Digital Health News